Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.77 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.57 |
| ▸ | AXL | P30530 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.56 |
| ▸ | CLK2 | P49760 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487600 | 0.93 | CAMKK2 (0.79) | CAMKK2AXLCDK8TNIKCLK2 | |
| SCHEMBL8258599 | 0.91 | CAMKK2 (0.67) | CAMKK2AXLCDK8TNIKCLK4 | |
| SCHEMBL8321118 | 0.90 | CAMKK2 (0.75) | CAMKK2AXLCDK8TNIKKIT | |
| SCHEMBL13753941 | 0.90 | CAMKK2 (0.78) | CAMKK2AXLCDK8TNIKCLK1 | |
| SCHEMBL8321116 | 0.89 | CAMKK2 (0.74) | CAMKK2DYRK1AKITAAK1 | |
| SCHEMBL13746116 | 0.88 | CAMKK2 (0.73) | CAMKK2AXLCDK8TNIKKIT | |
| SCHEMBL13745627 | 0.88 | CAMKK2 (0.67) | CAMKK2AXLCDK8TNIKKIT | |
| SCHEMBL8321210 | 0.88 | CAMKK2 (0.70) | CAMKK2AXLCDK8TNIKDYRK1A | |
| SCHEMBL13745445 | 0.87 | CAMKK2 (1.00) | CAMKK2AXLCLK2DYRK1ACLK4 | |
| SCHEMBL13753981 | 0.86 | CAMKK2 (0.74) | CAMKK2AXLCDK8TNIKKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | CAMKK2 94/4885MAP3K11 23/4885AXL 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.